Skip to main content
NUTRITION 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session: Dietary Micronutrient and Supplementation in Population (Oral 4)

(OR04-02-24) Dietary Biotin Associated With Psychological Disorders: A Prospective Study Based on 210, 907 Participants in UK Biobank

Saturday, June 29, 2024
3:12 PM – 3:24 PM CT
Location:  W375A

    Presenting Author(s)

  • Yuefeng Tan, PhD

    Student
    Tsinghua University
    Beijing, Beijing, China (People's Republic)

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • AZ

    Ai Zhao

    Vanke School of Public Health, Tsinghua University

  • Junhan Zhang, MASTER

    student
    Tsinghua University
    Beijing, Beijing, China (People's Republic)

  • Xiaona' Na, PhD. (she/her/hers)

    Student
    Tsinghua University
    Beijing, Beijing, China (People's Republic)

  • CY

    Celi Yang

    Tsinghua University, Vanke School of Public Health, Beijing, China (People's Republic)

Objectives: Biotin, implicated in nervous system and gut microbiota, served as a potential functional nutrient in promoting mental health. However, population based prospective studies are rare. This study aimed to explore the association of dietary biotin with major depressive disorders (MDD), anxiety disorders (AXD), and other mood disorders (OMD). Mediation effects were also examined.

Methods: Data of 210,907 participants from UK Biobank, a prospective cohort, were utilized. Dietary assessments relied on 24-hour dietary recalls, and average biotin intake during follow-up was calculated then categorized by quantiles. Cox hazard regression models, adjusted for confounders, were used to assess biotin association with different types of psychological disorders. Restricted cubic spline analysis was used to explore nonlinear relationships. Polygenic risk scores (PRS) for MDD were calculated using 100 genetic variants and allowed for a PRS-stratified analysis.

Results: The incidence rates per 1000 person-years for MDD, AXD, and OMD were 2.58, 3.81, and 0.19, respectively. Higher average biotin intake was significantly associated with lower MDD (Q2: HR=0.85, 95% CI: 0.79-0.92; Q3: HR=0.89, 95% CI: 0.81-0.97; Q4: HR=0.84, 95% CI: 0.76-0.93) and AXD (Q2: HR=0.90, 95% CI: 0.85-0.96; Q3: HR=0.87, 95% CI: 0.81-0.93; Q4: HR=0.86, 95% CI: 0.79-0.92), but not OMD(Q2: HR=1.09, 95% CI: 0.82-1.44; Q3: HR=1.08, 95% CI: 0.79-1.47; Q4: HR=1.31, 95% CI: 0.94-1.82). A U-shaped relationship between MDD and biotin showed an optional intake of biotin is around 45 μg/d. Mediation effects of obesity (β=0.011, 95% CI -0.044 - -0.002) and c-reactive protein (β=0.013,0. 95% CI: -0.053 - -0.003) were significant. In stratified analysis, population heterogeneity was identified. Specifically, among participants aged over 60 years, only the highest intake was related to lower MDD (Q4: HR=0.79, 95% CI: 0.67-0.92). Biotin was not associated with MDD in participants with high intake of other B vitamins or high PRS.

Conclusions: Our study revealed the benefits of biotin intake in psychological disorders depend on its dosage, showing U-shaped associations with MDD and AXD. The heterogeneous effects of biotin on various population requires further studies to clarify its optimal intake and explore the possible mechanism.

Funding Sources: No funding source for this study.